This IPO contains both fresh issues as well as an offer for sale (OFS). In the fresh issue, it contains equity shares worth ₹500 crore, and in an OFS, it contains shares worth ₹585 crore, according to DRHP. General Atlantic Singapore RR Pte Limited is the promoter that is selling shares in OFS. General Atlantic currently holds over 57% of Rubicon Research.
The company has declared its plan to apply the ₹310 crore in proceeds from the new issue towards the settlement of the remaining debts. The money will also be utilized for general business needs, other strategic projects, and inorganic growth through unnamed acquisitions.
As a specialized pharmaceutical company, Rubicon Research is dedicated to creating products of the highest quality for the worldwide market by utilizing modern technology. Their dedication lies in creating value-added formulations that have an impact on people’s lives globally.
The pharmaceutical company has two research and development (R&D) facilities in India and Canada that have been inspected by the US FDA. It also runs two manufacturing plants in India that are recognized by numerous regulatory bodies, such as Health Canada, the United States Food and Drug Administration, and Maharashtra (which holds a WHO-GMP accreditation).
Rubicon Research has a strong portfolio until March 31, 2024, with 69 products approved by the USFDA, 46 products in various phases of development, and 19 new drugs pending approval.
The issue’s book-running lead managers are SBI Capital Markets, Axis Capital, and IIFL Securities.
Rubicon Research is well-positioned to expand its market presence and provide high-quality pharmaceutical solutions around the world because of its solid portfolio and strategic growth plans. The upcoming IPO marks a significant milestone in their mission to drive innovation in the healthcare industry.
